Clementia Pharmaceuticals Inc (CMTA) Expected to Post Earnings of -$0.44 Per Share

Equities analysts expect Clementia Pharmaceuticals Inc (NASDAQ:CMTA) to post earnings of ($0.44) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Clementia Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.39) and the lowest estimate coming in at ($0.50). Clementia Pharmaceuticals posted earnings per share of ($0.37) in the same quarter last year, which would indicate a negative year over year growth rate of 18.9%. The firm is scheduled to announce its next quarterly earnings report on Wednesday, February 27th.

On average, analysts expect that Clementia Pharmaceuticals will report full-year earnings of ($1.65) per share for the current financial year, with EPS estimates ranging from ($1.78) to ($1.58). For the next fiscal year, analysts anticipate that the firm will post earnings of ($1.82) per share, with EPS estimates ranging from ($2.13) to ($1.47). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that follow Clementia Pharmaceuticals.

Clementia Pharmaceuticals (NASDAQ:CMTA) last announced its quarterly earnings data on Wednesday, November 7th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.04).

Several equities analysts have recently weighed in on CMTA shares. Wedbush reiterated an “outperform” rating and set a $26.00 price objective on shares of Clementia Pharmaceuticals in a report on Friday, August 10th. Morgan Stanley dropped their price objective on shares of Clementia Pharmaceuticals from $27.00 to $26.00 and set an “overweight” rating on the stock in a report on Monday, August 13th. Zacks Investment Research upgraded shares of Clementia Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, August 13th. Finally, B. Riley dropped their price objective on shares of Clementia Pharmaceuticals from $25.00 to $16.00 and set a “buy” rating on the stock in a report on Wednesday, August 15th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $19.75.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Trexquant Investment LP acquired a new stake in shares of Clementia Pharmaceuticals in the 3rd quarter worth about $126,000. Birchview Capital LP raised its holdings in shares of Clementia Pharmaceuticals by 78.9% in the 2nd quarter. Birchview Capital LP now owns 68,000 shares of the company’s stock worth $895,000 after acquiring an additional 30,000 shares during the last quarter. Opaleye Management Inc. acquired a new stake in shares of Clementia Pharmaceuticals in the 3rd quarter worth about $1,660,000. Artal Group S.A. raised its holdings in shares of Clementia Pharmaceuticals by 246.0% in the 3rd quarter. Artal Group S.A. now owns 692,000 shares of the company’s stock worth $7,716,000 after acquiring an additional 492,000 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Clementia Pharmaceuticals by 17.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,037,047 shares of the company’s stock worth $11,563,000 after acquiring an additional 155,336 shares during the last quarter. Hedge funds and other institutional investors own 72.27% of the company’s stock.

Shares of NASDAQ CMTA traded down $0.27 during trading on Friday, hitting $13.96. 29,620 shares of the company traded hands, compared to its average volume of 88,302. Clementia Pharmaceuticals has a fifty-two week low of $8.10 and a fifty-two week high of $20.15. The firm has a market capitalization of $442.78 million, a P/E ratio of -1.76 and a beta of -2.07.

Clementia Pharmaceuticals Company Profile

Clementia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial.

Featured Story: Benefits of owning preferred stock

Get a free copy of the Zacks research report on Clementia Pharmaceuticals (CMTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Clementia Pharmaceuticals (NASDAQ:CMTA)

Receive News & Ratings for Clementia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit